EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

MeCP2 Dosage Control in Rett Syndrome: Non-Coding RNA-Based and Epigenetic Strategies for Safer Gene Therapy

Ilyas M Kabdesh, Albert A Rizvanov iD, Yana O Mukhamedshina iD

Non-Coding RNA · 22.07.2026 · 12 (4) · 25

DOI: 10.3390/ncrna12040025 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Non-Coding RNA, online erschienen am 22.07.2026. Verfasst von Ilyas M Kabdesh und 2 weiteren Autor:innen. Beteiligte Einrichtung: OpenLab «Gene and Cell Technologies», Institute of Fundamental Medicine and Biology, Kazan (Volga Region) Federal University, 420021 Kazan, Russia. Die Arbeit nennt 69 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Tatarstan Academy of Sciences.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Rett syndrome (RTT) is a severe X-linked neurodevelopmental disorder that is caused in most cases by pathogenic variants in MECP2, the gene encoding methyl-CpG-binding protein 2 (MeCP2). Despite substantial progress in the development of gene therapy, restoring MECP2 expression remains challenging because MeCP2 is highly dosage-sensitive. Both deficiency and excessive expression of this protein are associated with severe neurological abnormalities. This makes simple viral vector-mediated replacement of MECP2 potentially unsafe and underscores the need for multilayered systems that control transgene expression. This review discusses current and emerging strategies for regulating MeCP2 expression in RTT, with an emphasis on non-coding RNA-based and epigenetic mechanisms. Particular attention is given to the limitations of conventional AAV-mediated gene therapy, the use of cell-specific and endogenous promoters, miRNA-regulated elements, autoregulatory systems, and post-transcriptional control of MECP2 expression. Strategies for reactivating the inactive X chromosome are also discussed, including XIST-dependent regulation and epigenome editing. In addition, the review considers CRISPR-mediated regulation, selective epigenetic activation, and combined therapeutic platforms that integrate viral delivery, RNA-dependent post-transcriptional control, and endogenous gene regulation. Overall, clinically applicable gene therapy for RTT will likely need to move beyond simple MECP2 replacement and instead rely on precise cell- and dose-dependent regulation of its expression. Non-coding RNA and epigenetic mechanisms represent important layers of such control and may contribute to the development of safer gene therapy strategies for RTT.

Schlagwörter

Stichwörter der Autor:innen

AAVCRISPR/dCas9MeCP2Rett syndromeX-chromosome reactivationepigenome editinggene therapymiRNAnon-coding RNA

Autor:innen und Institutionen

  • OpenLab «Gene and Cell Technologies», Institute of Fundamental Medicine and Biology, Kazan (Volga Region) Federal University, 420021 Kazan, Russia.
  • Division of Medical and Biological Sciences, Tatarstan Academy of Sciences, 420013 Kazan, Russia.
  • Department of Histology, Cytology and Embryology, Kazan State Medical University, 420008 Kazan, Russia.

ORCID-Profile: Albert A Rizvanov, Yana O Mukhamedshina

Förderung

  • Tatarstan Academy of Sciences

Zitieren

APA

Kabdesh, I. M., Rizvanov, A. A., & Mukhamedshina, Y. O. (2026). MeCP2 Dosage Control in Rett Syndrome: Non-Coding RNA-Based and Epigenetic Strategies for Safer Gene Therapy. Non-Coding RNA, 12(4), 25. https://doi.org/10.3390/ncrna12040025

Vancouver

Kabdesh IM, Rizvanov AA, Mukhamedshina YO. MeCP2 Dosage Control in Rett Syndrome: Non-Coding RNA-Based and Epigenetic Strategies for Safer Gene Therapy. Non-Coding RNA. 2026;12(4):25. doi:10.3390/ncrna12040025

BibTeX
@article{Kabdesh2026,
  author = {Kabdesh, Ilyas M and Rizvanov, Albert A and Mukhamedshina, Yana O},
  title = {MeCP2 Dosage Control in Rett Syndrome: Non-Coding RNA-Based and Epigenetic Strategies for Safer Gene Therapy},
  journal = {Non-Coding RNA},
  year = {2026},
  volume = {12},
  number = {4},
  pages = {25},
  doi = {10.3390/ncrna12040025}
}
Kostenlos starten →